CClinicalTrials.gg
Active, not recruitingNCT07749235Updated Aug 6, 2026

The Effect of the Helfer Skin Tap and Buzzy Application on Vaccination Pain, Fear and Crying Duration

An interventional study of Bee Buzzy and Helfer Skin TAp in Pain, Fear and Crying, sponsored by Ege University. Active, not recruiting at 1 site in Turkey (Türkiye). Open to participants aged 9 Months to 12 Months. Per ClinicalTrials.gov, last updated 2026-08-06.

Sponsored by Ege University · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
9 Months to 12 Months
Sex
All
01

Study summary

To minimize the pain and discomfort during vaccination, one of three different methods will be used. One method involves using 'Buzzy,' a small, bee-shaped device that provides vibration and a cooling sensation; another involves massaging the injection site by tapping it rhythmically with our fingertips; and the third follows the standard vaccination procedure. Participants will be randomly assigned to the group.

02

Conditions studied

  • Pain
  • Fear
  • Crying

Browse trials for

Keywords

  • infant
  • vaccination
  • pain
  • fear
  • crying
03

In context

Pain

2,219 studies on the registry are indexed under Pain; 917 are open to participants now.

This study's enrollment of 90 is above the median of 70 across 1,904 interventional studies indexed under Pain.

Browse Pain studies →

Lead sponsor

Ege University is the lead sponsor of 365 studies on the registry; 46 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
9 Months to 12 Months
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Birth between the 38th and 42nd weeks of gestation
  • Having completed the 9th month postpartum
  • Being followed under the standard immunization program in accordance with the national vaccination schedule.
  • Babies of mothers who can speak and understand Turkish

Exclusion criteria

Exclusion Criteria:

  • Having an acute or chronic illness
  • Having a history of allergies
  • Presence of nerve damage or limb deformity at the injection site
  • Having received analgesic treatment within the 24 hours prior to immunization
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    Bee Buzzy

    Buzzy the Bee will be used on the patient during the 9-month vaccination procedure. Thanks to its cold wings and vibration, Buzzy reduces pain and helps distract the patient during the injection, thereby alleviating feelings of pain and fear. Buzzy will be placed 5 cm above the injection site; after a 15-second wait, the actual vaccination will be administered.

    Device: Bee Buzzy

  • Experimental
    Helfer Skin Tap (HST) Technique Group:

    HST technique maneuvers will be applied to the 9-month-old infants in this group during vaccination. HST consists of a four-stage tapping sequence. The administering nurse will perform approximately 10 taps over a 5-second period using the palmar surface of the dominant hand's fingers to relax the leg muscles at the injection site (Stage 1). Following skin disinfection, the nurse will position the thumb and index finger of the non-dominant hand in a V-shape and perform 3 taps on the injection site using the palmar surface of those fingers (Stage 2). Simultaneously with the third tap, the nurse will insert the needle into the muscle at a 90-degree angle while continuing to tap the skin lightly with the palmar surface of the non-dominant hand's fingers (Stage 3). Once the medication has been fully administered, the nurse will perform 3 taps on the skin with the palmar surface of the non-dominant hand's fingers and withdraw the needle simultaneously with the final tap (Stage 4).

    Behavioral: Helfer Skin TAp

  • No intervention
    control group

    No intervention other than the administration of the vaccine by the nurse will be performed on the 9-month-old infant in this group. The 9-month-old infant will receive routine vaccination.

Interventions

  • DeviceBee Buzzy

    Buzzy the Bee will be attached to the leg where the 9-month-old infant-included in this group by the researcher-is to receive the vaccine. Thanks to its cold wings and vibration, Buzzy the Bee reduces pain; it helps distract attention during the vaccination process, thereby alleviating feelings of pain and fear. Buzzy the Bee will be secured 5 cm above the injection site, and the nurse will administer the vaccine after a 15-second wait.

  • BehavioralHelfer Skin TAp

    HST technique maneuvers will be applied to the 9-month-old infants in this group during vaccination. HST consists of a four-stage tapping sequence. The administering nurse will perform approximately 10 taps over a 5-second period using the palmar surface of the dominant hand's fingers to relax the leg muscles at the injection site (Stage 1). Following skin disinfection, the nurse will position the thumb and index finger of the non-dominant hand in a V-shape and perform 3 taps on the injection site using the palmar surface of those fingers (Stage 2). Simultaneously with the third tap, the nurse will insert the needle into the muscle at a 90-degree angle while continuing to tap the skin lightly with the palmar surface of the non-dominant hand's fingers (Stage 3). Once the medication has been fully administered, the nurse will perform 3 taps on the skin with the palmar surface of the non-dominant hand's fingers and withdraw the needle simultaneously with the final tap (Stage 4).

06

What researchers measure

Primary outcomes

  1. Children's Fear Scale

    The Fear Facial Expression Scale was adapted for adults as "The Faces Anxiety Scale" by McKinley et al. (2003). The same scale was subsequently adapted for pediatric medical contexts as the "Children's Fear Scale" by McMurtry et al. (2011). This scale features five distinct facial expressions. It is scored on a scale of 0 to 4 and is recognized as a reliable and valid measurement tool for assessing fear. A study on its Turkish validity and reliability, conducted by Binay Yaz and Bal Yılmaz (2019), demonstrated that the scale is a reliable instrument for measuring fear of medical treatment and surgical procedures across all pediatric age groups.

    Time frame: Periprocedural

  2. Wong-Baker Faces Pain Rating Scale-WBFPRS

    It is the most frequently used scale for pain assessment in pediatric patients because it has been reported to effectively differentiate pain levels across all age groups of children. Six (6) facial expressions, rated from 0 to 10 based on the presence and severity of pain, are utilized. The facial expressions are categorized as follows: "0" (smiling/no pain), 1-2 ("hurts a little"), 3-4 ("hurts a little more"), 5-6 ("hurts even more"), 7-8 ("hurts a lot"), and 9-10 ("hurts the most"). This scale does not require verbal expression or numerical values and serves as a reliable and valid measurement tool for assessing acute pain.

    Time frame: Periprocedural

  3. Crying Duration

    Time frame: Periprocedural

07

Study locations

1 site
  • Private Medicana Bursa Hospital
    Bursa, Nilüfer, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Icf

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07749235
Lead sponsor
Ege University
Responsible party
Furkan Torun (Phd Candidate, Ege University) — Principal investigator
First posted
Aug 6, 2026
Start date
Jul 27, 2026
Primary completion
Dec 29, 2026 (estimated)
Completion
May 29, 2027 (estimated)
Last update
Aug 6, 2026

Study contacts

Hatice BAL, Prof. Dr.
study director · Ege University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion